References and Further Reading

Trying to get a good overview of genomics right now is surprisingly difficult.

Textbooks are too slow—by the time they explain the basics properly, half the exciting new stuff has already moved on. Scientific papers are essential, but they are often hard to read unless you already know the field—and even then, they usually explain the experiment, not why it matters for society, healthcare, food, policing, biodiversity or your own life.

A lot of the most interesting work is not happening in neat, public, easy-to-follow places. It is happening inside biotech startups, clinical genomics units, pharmaceutical companies, national genome programmes, AI labs, diagnostic companies, research hospitals and venture-backed companies that may or may not still exist in three years.

Why genomics is so hard to follow

Genomics is moving through several worlds at once. It is a science, a medical technology, a data industry, a business opportunity, a political issue, a privacy problem, a biodiversity tool, a defence concern. It is also, increasingly, part of ordinary life. That means no single source can really cover it.

A paper in Nature might explain a new genome-editing method. A biotech newsletter might explain which company just raised hundreds of millions to commercialise something similar. A clinical genomics programme might show how sequencing is being used in hospitals. A policy report might explain why the law is already behind. A podcast interview with a founder might reveal where the industry is heading before the academic literature catches up. None of them will give you the full picture of how it matters to you, and how the lives of millions will be affected by it.

To understand The Genomic Power Shift, you need to read across all of those layers, and currently, without a PhD in genetics and AI, it is very hard to make sense of it.

Where the action is happening

The new genomics economy is clustered in many of the same places where biotechnology, AI, medicine and venture capital already meet. That includes the San Francisco Bay Area, San Diego, Boston and Research Triangle Park in the United States; London, Oxford and Cambridge in the United Kingdom; Berlin-Brandenburg in Germany; Zürich and Basel in Switzerland; Singapore; Shanghai; Tel Aviv; Dubai and Abu Dhabi; Hyderabad, sometimes called India’s Genome Valley; and Bangalore.

Increasingly, large investments are being made by national healthcare systems, university hospitals, diagnostic laboratories, pharmaceutical companies, agricultural technology firms, conservation organisations and government-backed genome programmes. In Europe, public healthcare and national research infrastructure are playing an enormous role. In the United States, commercial healthcare, private diagnostics and venture-backed biotechnology are major forces. In Asia, several countries are building powerful genomics, AI and biomanufacturing ecosystems at high speed. The result is messy, exciting and hard to track.

What to read if you want to keep up

If you want to follow genomics as it actually develops, it helps to mix different kinds of sources.

For the science, follow journals and research organisations that publish work on genomics, genome editing, precision medicine, biodiversity, AI in biology and molecular diagnostics. Examples include Nature Biotechnology, Nature Genetics, Genome Biology, the Broad Institute, the National Human Genome Research Institute, EMBL-EBI, the Wellcome Sanger Institute and similar research centres.

For biotech business and industry news, follow specialist outlets that cover companies, deals, clinical trials, drug development, diagnostics, gene therapy and venture capital. Useful starting points include GenomeWeb, Precision Medicine Online, STAT, Endpoints News, Fierce Biotech and Labiotech.

For a more conversational view of the field, podcasts and newsletters can be much easier to follow than academic papers. They often explain not just what happened, but why people in the field are excited, worried or throwing money at it. Good places to start include The Readout from STAT, The Readout Loud, Nature Biotechnology’s news and commentary, GenomeWeb newsletters, Labiotech, and biotech or health-focused podcasts such as Raising Health.

For basic definitions, it is often better to use trusted educational resources than random internet summaries. The National Human Genome Research Institute’s Talking Glossary is one of the clearest places to look up genetics and genomics terms, as is our glossary.

People matter too

One of the best ways to understand a fast-moving field is to follow the people shaping it. That might mean scientists working on CRISPR, clinical genomics, AI biology, rare disease, population genetics, biodiversity genomics, bioethics or synthetic biology. It might also mean founders, investors, clinicians, policy experts, patient advocates and science journalists.

In genomics, the most useful people are often the ones who can explain both the promise and the limits. They know when a result is genuinely important and when it is mostly hype.

How to read scientific papers without losing the will to live

You do not need to understand every method in a genomics paper to learn from it. Start with three questions: What did they actually do? What did they find? Why does anyone care?

Then ask three more: Was this done in cells, animals, patients or a computer model? Is it a proof of concept, or something already useful? Who benefits if this becomes real?

That last question is often the most important one. A genomics paper can be scientifically brilliant and still be years away from changing medicine. A biotech company can sound revolutionary and still have no working product. A genetic risk score can be statistically significant and still not be very useful for you personally. Reading genomics well means learning to separate hype and impact.

Suggested starting points

If you are new to genomics, start with the basics: DNA, genes, genomes, sequencing, CRISPR, inheritance, rare disease, cancer genomics and genetic testing.

If you are interested in medicine, follow precision medicine, rare disease diagnostics, cancer genomics, pharmacogenomics, newborn sequencing and clinical trials.

If you are interested in society, follow genomic privacy, forensic DNA, reproductive genetics, embryo selection, bioethics, Indigenous data rights and genetic discrimination.

If you are interested in the future, follow AI in biology, synthetic biology, gene editing, cell therapies, biomanufacturing, biosecurity and biodiversity genomics.

If you are interested in money, follow biotech venture capital, pharma partnerships, diagnostics companies, sequencing platforms, clinical genomics infrastructure and the companies trying to turn biology into an engineering discipline.

Most importantly—your active interest in the topics, and your opinions matter! Genomics is not for the boffins or the investors—it is all of our futures at stake.

A note on hype

Genomics attracts hype because it sits at the intersection of three things people love to exaggerate: medicine, data and the future.

Be sceptical of anything that promises to decode your destiny, cure all disease, optimise your child, reverse ageing, solve biodiversity collapse or make biology fully programmable next quarter. But at the same time—we are already seeing things actually being implemented which are nothing short of miraculous—blind people regaining sight, mice with 50% increased lifespan, rare and deadly diseases cured, a pandemic averted with effective vaccines.

But as with all of these very powerful transformative technologies, there are significant challenges: who decides who gets a treatment? What happens to all of humanity if we make designer babies—even if you don’t, they might end up having children with your children.

How this book uses references

The Genomic Power Shift draws on scientific papers, clinical genomics, public databases, policy documents, historical examples, industry developments, ethical debates and the author’s own experience working in genomics and bioinformatics.

The aim is not to make the reader wade through hundreds of references before understanding the point. The aim is to translate the field into a form that is readable, useful and connected to real life.

Reading this book will change your perspective and understanding, and hopefully make you feel more empowered to engage, and make decisions for yourself and your family, your children, born and not yet born, and their children too.